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Abstract
Metabolic remodeling is now widely regarded as a hallmark of cancer, but it is not clear whether
individual metabolic strategies are frequently exploited by many tumours. Here we compare
messenger RNA profiles of 1,454 metabolic enzymes across 1,981 tumours spanning 19 cancer
types to identify enzymes that are consistently differentially expressed. Our meta-analysis
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trecovers established targets of some of the most widely used chemotherapeutics, including
dihydrofolate reductase, thymidylate synthase and ribonucleotide reductase, while also
spotlighting new enzymes, such as the mitochondrial proline biosynthetic enzyme PYCR1. The
highest scoring pathway is mitochondrial one-carbon metabolism and is centred on MTHFD2.
MTHFD2 RNA and protein are markedly elevated in many cancers and correlated with poor
survival in breast cancer. MTHFD2 is expressed in the developing embryo, but is absent in most
healthy adult tissues, even those that are proliferating. Our study highlights the importance of
mitochondrial compartmentalization of one-carbon metabolism in cancer and raises important
therapeutic hypotheses.
Introduction
Divergent metabolism in tumors was first recognized nearly a century ago 1, and is
consistently observed across a number of tumor types, and has been exploited for diagnostic
as well as therapeutic purposes. For example, rapid glucose consumption in tumors may be
imaged by positron emission tomography (PET) and used to diagnose malignancy and to
monitor the response to therapy 2. Furthermore, the dependence of cancer cells on nucleotide
metabolism forms the basis for the use of several common chemotherapeutics, including
agents targeting dihydrofolate reductase (DHFR), thymidylate synthase (TYMS) and
ribonucleotide reductase (RRM2) 3. Moreover, recent data has suggested that many of the
growth factor signaling pathways commonly perturbed in cancer impinge on metabolic
enzymes 4, as well as that metabolic enzymes may act as bona fide oncogenes 5 and even
transform cells 6. Collectively, these observations underscore the need for a deeper
understanding of metabolic reprogramming in cancer. While classic biochemical studies
have identified a number of enzymes whose activities are increased in cancers 7,8, the
complex, coordinated changes in metabolism that occur during cancer transformation have
only begun to be understood 9.
Over the past decade, a wealth of data on tumors, normal tissues and cell models have been
generated using microarrays and analyzed to identify genes differentially expressed in
cancer 10,11. These data provide a unique opportunity to study expression patterns of
metabolic enzymes in cancer and thereby define the metabolic program of cancer on a
genome-wide scale 9. Yet, as most studies have compared tumor tissue to a quiescent,
postmitotic normal control tissue, these analyses do not indicate whether enzymes over-
expressed in tumors are also active in proliferative normal tissues. Identification of cancer-
specific metabolic activities is essential, as current chemotherapeutic agents target metabolic
enzymes found both in transformed cells as well as normal proliferating cells, notably
immune cells, hair follicles and intestinal epithelium, resulting in the on-target side effects in
proliferative tissues that limit these agents’ therapeutic index 3.
Here we report a systematic re-analysis of previously published microarray datasets,
focusing on genes known or predicted to encode metabolic enzymes, and identify several
enzymes and pathways consistently over-expressed or under-expressed across a large
number of different cancer types. In particular, we find that enzymes of the mitochondrial
folate metabolic pathway, which are ordinarily low or absent in normal adult tissues, are
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thighly upregulated in cancer. Finally, we show that the MTHFD2 enzyme in this pathway is
highly expressed on the protein level in a variety of human tumors and negatively correlates
with survival in breast cancer patients.
Results
Meta-analysis of enzyme mRNA expression in human tumors
To systematically investigate expression of metabolic pathways across multiple tumor types,
we first searched the GeneChip Oncology Database (GCOD) 10 for studies containing
primary tumor tissue samples and suitable normal tissue controls. We found 51 independent
datasets satisfying this criterion, covering a total of 1,981 tumors of 19 different types vs.
931 matched normal tissue controls (Supplementary Data 1), and interrogating a total of
20,103 genes. To avoid artifacts from comparison across different array platforms and
laboratories, we calculated differential expression (quantified by Z-scores) within each
dataset, and estimated statistical significance for each gene by permutation tests. While the
extent of differential expression varied widely across studies (Fig. 1a) — likely reflecting
variability in tumor types, nature of the control tissue, and experimental design — we
reasoned that genes consistently differentially expressed across these cancers would
represent processes of fundamental importance to transformed cells. We therefore scored
each gene by counting the number of datasets where differential expression was detected at
a 5% false discovery rate (Fig. 1b, full genome wide analysis available as Supplementary
Data 2). Most high-scoring over-expressed genes have previously been found to be
expressed in the “committed” S, G2 and M phases of the cell cycle 12,13, where cells are
thought to be most vulnerable to pharmacologic intervention. This likely reflects the high
proportion of proliferating cells in tumors compared to control tissues.
We focused our analysis on 1,454 metabolic enzymes annotated in a previously established
model of the human metabolic network 14. Among the top 50 consistently over-expressed
enzymes (Table 1), we recovered several metabolic pathways previously associated with
cancer, including multiple enzymes involved in glycolysis 15, de novo synthesis and salvage
of nucleotides 7 and in particular deoxynucleotides, as well as prolyl hydroxylases
responsive to hypoxia 16 and glycosylation enzymes 17 (Fig. 1c, d), in agreement with a
recent independent study 9. Among these metabolic enzymes, we recovered a number of
genes targeted by existing cancer therapeutics, including DHFR (the target of methotrexate),
TYMS (the target of 5-fluorouracil), and RRM2 (the target of gemcitabine) (Fig. 1b, Table 1).
Beyond metabolic enzymes, our analysis also identified a number of other enzyme targeted
by chemotherapeutics, including topoisomerase 2A (TOP2A), aurora A kinase (AURKA),
and cyclin-dependent kinase 4 (CDK4) (Fig 1b, Supplementary Data 2), as consistently
over-expressed in cancers. Hence, our systematic analysis of metabolic reprogramming
identifies a number of establish cancer-related metabolic enzymes and pathways across
varied tumor types.
Our analysis additionally reveals several metabolic enzymes consistently under-expressed in
cancer and whose roles in cancer have not been previously appreciated. Among the
metabolic enzymes consistently underexpressed in cancer (Table 2), we noted a number of
enzymes related to fatty acid metabolism, including catabolism of branched fatty acids
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t(ACOX2, ETFDH), synthesis of ketones (HMGCS2) and fatty acid synthesis (ACCB). A
number of antioxidant enzymes were also consistently down-regulated in cancer (Fig. 1c,
Table 2). Taken together, these findings suggest consistent down-regulated metabolic
pathways and enzymes across multiple tumor types which remain to be explored.
Cancer cells have previously been proposed to exhibit stem cell like properties, expressing
genes characteristically found in embryonic cells 18. Of the 35 enzymes previously
established to be expressed by embryonic stem cells 18, a large fraction were over-expressed
in tumors (Fig. 1e), suggesting a tendency to revert to a embryonic-like metabolic program.
Among the top 50 consistently over-expressed enzymes (Table 1) identified in our study, 26
enzymes have previously been evaluated using large-scale RNAi screening to determine
those essential for tumorgenesis in vitro and in vivo in breast cancer cells 19. Among these
26 metabolic genes, 6 genes (CTPS, GAPDH, PYCR1, MTHFD2, TPI1, and TSTA3) were
found to be require for tumorgenesis in vitro and 5 genes (CTPS, GAPDH, GMPS, PYCR1
and TPI1) in vivo 19. Whereas several of these genes are components of glycolytic or
nucleotide metabolism pathways previously associated with tumorgenesis, TSTA3, PYCR1,
and MTHFD2 are members of pathways less appreciated in the context of cancer. TSTA3
catalyzes the production of GDP-L-fucose (Fig. 1c), which serves as the substrate for
fucosyltransferases reactions. Increased levels of GDP-L-fucose and fucosylated
glycoproteins have been noted in cancer 20, their role in tumorgenesis remains unclear.
Similarly, our analysis also identified the mitochondrial enzyme PYCR1 (Fig. 1c), an
established target of the oncogene myc 21. PYCR1 catalyzes the final step of proline
synthesis from glutamate (Fig. 1c), including in cancer cells 22. In conjunction with its
cytosolic isoform, PYCR1 may serve as a cycle for the transfer of reducing equivalents from
the cytosol into the mitochondria 23, modulating both intracellular redox status 24 and
sensitivity to oxidant injury 25.
Among all 1,454 enzymes examined, the metabolic enzyme most consistently overexpressed
in tumors was the mitochondrial folate-coupled dehydrogenase MTHFD2 (Fig. 1a, b),
ranked within the top 3 of all 20,103 genes interrogated (Supplementary Data 2). MTHFD2
is integral to mitochondrial one-carbon metabolism (Fig. 1d), a metabolic system recently
implicated in rapid cancer cell proliferation 26. MTHFD2 is a bifunctional enzyme,
catalyzing the NAD+ dependent CH2-THF dehydrogenase and CH+-THF cyclohydrolase
reactions within the mitochondria 27. Within mitochondrial one-carbon metabolism, we also
noted frequent overexpression of the preceding enzyme, SHMT2, which catalyzes the
production of glycine and one-carbon groups in the form of CH2-THF from serine (Fig. 1d).
The subsequent enzyme, MTHFD1L, catalyzing the synthesis of formate and regeneration of
the THF cofactor (Fig. 1d), was only measured on 11/51 microarrays, so that our meta-
analysis was not well-powered in this case; however, it appeared consistently over-
expressed in those 11 datasets (data not shown). In the paralogous cytosolic one-carbon
pathway, the NADP+-linked, trifunctional MTHFD1 enzyme also exhibited over-expression
in multiple cancers, although it did not reach top 50 threshold (Fig. 1d). This is consistent
with the notion that the mitochondrial one-carbon system serves to produce formate which is
then again coupled to THF in the cytosol by the MTHFD1 enzyme 27. Interestingly, the
cytosolic enzyme ALDH1L1, which breaks down cytosolic formyl-THF into CO2 and THF
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tand thus opposes the synthesis of one-carbon units, was consistently under-expressed in
tumors (Fig. 1d, Table 1). The paralogous mitochondrial enzyme, ALDH1L2 was not
reliably measured on the microarray platforms used (Fig. 1d). The aminomethyltransferase
AMT, a component of the enzyme system that catabolizes glycine, was also under-expressed
(Fig. 1d, Table 2). These findings suggest that the metabolic pathway channeling one-carbon
units through the mitochondria via MTHFD2 has an important role in cancer biology.
Enzymes in transformed and normal proliferating cells
Many of the metabolic changes accompanying transformation are also active in normal
proliferating cells 4. To identify cancer-related metabolic enzymes more specific to the
transformed state, we analyzed gene expression from 80 normal human tissues, including
proliferative tissues such as intestine and bone marrow, compared to transformed cell lines.
The well-known chemotherapeutic targets DHFR, RRM2, TYMS and TOP2A were expressed
in several normal proliferating cell types (Fig. 2a), in which the adverse side-effects of drugs
targeting these enzymes are commonly observed. In contrast, MTHFD2 exhibited little
expression in these tissues, and was in fact the most cancer-specific mRNA measured on
these arrays, as quantified by a transformed/normal expression ratio (Fig. 2b). In this
analysis we also noted the PYCR1 enzyme (Fig. 2b), which was also among the most
commonly over-expressed enzymes in cancer (Table 1). MTHFD2 was not detected upon
activation of serum-stimulated normal human fibroblasts in vitro, nor in hepatocytes
proliferating in vivo in response to partial liver resection (Fig. 2c), whereas other established
chemotherapeutic drug targets were induced also in these normal proliferating cells.
However, we did observe MTHFD2 induction at an early time point in activated
lymphocytes (Fig. 2c), consistent with previously observed MTHFD2 activity in bone
marrow 28, indicating a possible role for MTHFD2 in normal hematopoietic cells.
The MTHFD2 enzymatic activity has also previously been detected in embryonic fibroblasts
from the mouse 28 as well as in human embryonic stem cells 18, and knockout of the gene is
embryonic lethal in mice 29. We found that the MTHFD2 mRNA increases during the initial
rounds of cellular division in both mouse and human fertilized oocytes (Fig. 2d). In addition,
expression is high in mouse fetal liver and hypothalamus, but decreases markedly around
birth (Fig. 2e). These observations support a role for the enzyme in embryonic development.
RNA interference targeting MTHFD2 causes cancer cell death
To further evaluate whether expression of the MTHFD2 gene product is required for cancer
cell proliferation, we used two different RNAi modalities to silence MTHFD2 across 16
diverse cancer cell types. In total, we used 2 lentiviral delivered shRNA hairpins and 6
sequence-independent non-viral delivered siRNA oligonucleotides (Supplementary Fig. 1–
2). MTHFD2 mRNA, protein levels, and enzymatic activity were substantially reduced by
shRNA (Supplementary Fig. 1a–c, 3) or siRNA targeting MTHFD2 (Supplementary Fig.
1e). In most cell lines, proliferation was severely reduced, consistent with prior
observations 19, with noted variability in the degree of defect among the various cell lines
(Supplementary Fig. 1d, 1f). Propidium iodide staining and flow cytometry revealed marked
cell death at the 48 hour time point, with 40% of cells nonviable (Supplementary Fig. 1g, h),
while non-targeting control siRNA transfections did not impair cell viability (Supplementary
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tFig. 1i). While RNAi-mediated loss of the MTHFD2 gene product was associated with
slowed cancer cell proliferation and marked cell death, we have hitherto been unable to
rescue this phenotype by exogenous expression of the MTHFD2 cDNA, which is required to
definitively prove the effect is due to the enzymatic activity of MTHFD2 protein and not a
consequence of silencing its RNA or an off-target effect.
MTHFD2 protein expression in tumors and normal tissues
To evaluate if the MTHFD2 protein is overexpressed in human tumors, we performed
immunohistochemistry in 176 tumor samples, collected from 16 tumor types. Strong or
moderate staining for MTHFD2 was observed in 12 of these of tumor types, and the protein
was detectable in all cancer types with the exception of gliomas (Fig. 3a). While staining
intensity was variable across tumor samples, the protein consistently appeared specific to
transformed cells within the tumors, with little or no staining seen in adjacent stroma (Fig.
3b). These data indicate that the MTHFD2 protein is indeed present in multiple cancer types.
Activity of the enzyme has also previously been observed in transformed cell lines 30. We
did observe staining in normal epithelium of the gut tissues, in particular in intestinal crypts
containing stem cells, in tonsil lymphoid tissue and in exocrine pancreas (Supplementary
Fig. 4). Finally, we evaluated the expression of MTHFD2 in six independent cohorts of
patients with breast cancer followed for survival. Whereas there was heterogeneity among
individual data sets (Supplementary Fig. 5a), likely reflecting differences in the number of
patients and clinical parameters including, entry patient criteria and treatment strategies, a
meta-analysis of all six independent cohorts indicated that high expression of the MTHFD2
mRNA was associated with increased mortality in breast cancer patients (Supplementary
Fig. 5b), suggesting a potential role in tumor progression.
Discussion
In this study we have identified metabolic enzymes and pathways that are frequently over-
expressed in tumors, and demonstrated that one of these enzymes, MTHFD2, is broadly
required for cancer cell proliferation and viability. It should be emphasized that our meta-
analysis only addresses changes in enzyme expression at the mRNA level, and our results do
not exclude that other enzymes may be dysregulated in cancer by post-transcriptional
mechanisms such as translational control or allosteric regulation. Moreover, while our meta-
analysis was designed to reliably detect genes that are frequently over-expressed in tumors,
it will likely miss genes absent or not well measured on common microarray platforms, and
does not consider tissue-specific phenomena. Future studies investigating differences in
metabolic enzyme expression between tumor types, as well as co-occurrence of enzymes
and pathways in tumors, would be a valuable extension to this work.
Within our systematic analysis of metabolic reprogramming, we identified a number of
metabolic genes whose expression was altered in a variety of tumor types relative to normal
controls. Among the metabolic enzymes that were consistently over-expressed in tumors
(Table 1), we find a high proportion of established cancer-related metabolic enzymes and
known chemotherapeutic drug targets, suggesting that the additional enzymes identified here
may be of interest as cancer targets as well. These additional enzymes include MTHFD2 and
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tPYCR1, both of which are low or absent in a large panel of normal tissues, including the
proliferative tissues of the gut and a number of immune cell types; this could theoretically
limit on-target side effects typically associated with these cell types. We further demonstrate
the necessity of the MTHFD2 gene in cancer cell proliferation and survival across a number
of cancer cell lines. While the proliferation defect and early cell death phenotypes with
MTHFD2 knockdown were observed with multiple independent RNAi sequences, we cannot
definitively rule out off target RNAi effects. Moreover, while our results indicate a
requirement for the MTHFD2 mRNA, further studies are needed to prove that the MTHFD2
protein and its enzymatic activity are indeed mediating the observed effects on cancer cell
proliferation.
Genes consistently under-expressed in tumors include metabolic enzymes involved in fatty
acid metabolism, including catabolism of branched fatty acids, and ketogenesis as well as a
number of antioxidant enzymes (Table 2). The consistent repression of these metabolic
enzymes suggest a larger metabolic reprogramming that occurs with transformation in
varied tumor types, and may reflect an effort on the part of a cancer cell to shunt metabolites
to particular biosynthetic pathways rather than catabolism, to limit production of toxic
intermediates, and / or to preferentially shuttle reducing equivalents to particular
compartments, such as the mitochondria. As with the over-expressed metabolic genes,
further investigation of these under-expressed metabolic enzymes may uncover metabolic
vulnerabilities which may be targeted therapeutically.
While the enzymatic function of the MTHFD2 enzyme is well established, its broader role in
cancer cell metabolism is not yet clear. Interestingly, while SHMT2 knockdown renders
cancer cells auxotrophic for glycine 26, we find that MTHFD2 knockdown results in death of
human cancer cells in complete medium containing glycine (Supplementary Fig. 1g,h). This
observation indicates that the observed cell death upon loss of MTHFD2 is not due to
blocking of glycine synthesis. Moreover, as SHMT2 is thought to be the main source of
mitochondrial one-carbon units, this observation also suggests that depletion of formate, the
other main metabolic product of the mitochondrial one-carbon pathway, is unlikely to be the
cause of cell death upon loss of MTHFD2. In support of this hypothesis, we have been
unable to rescue the MTHFD2 defect with exogenous formate. Moreover, both normal and
transformed mouse embryonic fibroblasts lacking MTHFD2 are viable but auxotrophic for
glycine 31, suggesting that the strict dependence on MTHFD2 may be unique to human cells.
A recent report indicates that RNAi targeting MTHFD2 also affects cell migration and
invasion of human cancer cells. 32
The cell death observed upon MTHFD2 depletion may therefore be due to some type of
toxic event that does not arise in wild type cells and is unrelated to normal cellular
metabolism. One hypothesis is that, since MTHFD2 is considered required for recycling the
THF cofactor in mitochondria (Fig 1c), loss of the protein could result in mitochondrial
folates becoming “trapped” in the CH2-THF form, which would be detrimental to all folate-
coupled activities in the mitochondria. In addition, because CH2-THF cannot be transported
out of the mitochondria 27, folate trapping within the mitochondria with MTHFD2 silencing
could potentially impact a number of folate-dependent cytosolic reactions, as well. A similar
“folate trap” phenomenon has been observed upon loss of cytosolic folate-coupled enzymes,
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tincluding loss of methionine synthase 33. Alternatively, loss of MTHFD2 could result in
accumulation of an hitherto unknown toxic metabolite that rapidly causes cell death, perhaps
from unwanted side-reactions of metabolic enzymes occurring in the absence of
MTHFD2 34. While we have consistently observed cell death in response to several
independent RNAi sequences targeting MTHFD2, it must be emphasized that we have
hitherto not been able to rescue cell death by overexpression of an RNAi-resistant MTHFD2
cDNA, which is required to conclusively demonstrate that loss of this protein causes cancer
cell death.
While additional experiments are needed to understand the role of MTHFD2 function in
embryonic cells and in cancer, the specific expression of MTHFD2 in transformed cells
relative to other adult tissues, and the growth and survival defects caused by loss of the
mRNA suggests that this enzyme should be evaluated as a potential target for cancer
chemotherapeutics. More generally, the current analysis, combined with our previous
report 26 and other recent studies 6,19 points to a remodeling of mitochondrial one carbon
metabolism in cancer. Although it has long been appreciated that one-carbon folate
metabolism is compartmentalized within human cells, these recent studies indicate that
compartment-specific alterations may be critical to promoting cancer growth and survival.
The recognition that compartmentalization of one-carbon folate metabolism is altered in
cancer raises new opportunities for identifying novel therapies for cancer, as well as for
targeting with greater precision existing anti-folate therapies.
Methods
Microarray data analysis
Microarray data sets were selected from the GeneChip Oncology Database 10 (GCOD)
according to the following criteria: we considered only data sets of human tumors with
normal tissues samples as controls, excluding cell lines and cultured normal cells; we
required at least 3 independent samples in both tumor and control groups; and we considered
only data from the Affymetrix HG-Focus, HG-U133A, HG-U133Av2, HG-U133+v2,
HG_U95A, and HG_U95Av2 microarray platforms. A list of data sets included is provided
in Supplementary Data 1. All data sets were uniformly processed from the Affymetrix CEL
using the Robust multi-array average (RMA) algorithm, as described 10. For each
microarray platform, in cases of multiple probesets per gene, we selected the probeset with
maximal mean signal rank across all arrays. Differential expression between tumor and
normal groups was quantified for each data set using Z-scores, and nominal P-values of
differential expression were calculated for each gene using a permutation test (1,000
permutations). False discovery rates (FDR) were computed using the Benjamini-Hochberg
procedure 35. Meta-analysis of FDR was done by counting the number of times a gene was
over-expressed in tumors and subtracting the number of times it was under-expressed.
Enrichment analysis was done using the GSEA-p method 36 with the parameter p set to 1.
The compendium of 80 human tissues was generated from duplicate samples for each tissue
using Affymetrix U133A arrays 37. The gcRMA-normalized data was downloaded from
www.biogps.org, and duplicates were averaged for the analysis presented in Figure 2. Our
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tclassification of tissues and cells as normal/postmitotic, normal/proliferating or transformed
is described in Supplementary Table 1.
Expression data from proliferating human fibroblasts, human T cells, mouse regenerating
liver and mouse/human embryonic development was obtained from the NCBI Gene
Expression Omnibus, series accession GSE3945, GSE2770, GSE6998, and GSE18290,
respectively. No additional normalization was performed.
Cell culture
Human cancer cell lines (passage number 5–18 in all cases except HCT-116) were obtained
from the National Cancer Institute (NCI). All cell lines were cultured in RPMI-1640
medium (Invitrogen) with 2 mM L-glutamine and 5% fetal bovine serum (HyClone
Laboratories). Cells were cultured at 37°C in 5% CO2.
shRNA knockdown of MTHFD2
Cells were cultured according to standard techniques as described above. Lentiviral vectors
(pLKO.1) expressing shRNA clones were generated by the Broad RNAi Consortium, as
previously described 26. Sequence-independent shRNA’s were generated against human
MTHFD2 (sh50, sh53) or a control sequence (shCtrl) not matching any human gene.
Accession numbers are: shCtrl, Clone ID TRCN0000072232, Clone name lacZ_27s1c1,
Target sequence CGTCGTATTACAACGTCGTGA; shD2-50, Clone ID
TRCN0000036550, Clone name NM_006636.2-548s1c1, Target sequence
CGAATGTGTTTGGATCAGTAT; shD2-53, Clone ID TRCN0000036553, Clone name
NM_006636.2-772s1c1, Target sequence GCAGTTGAAGAAACATACAAT. The pLKO.1
plasmids were each packaged with VSVG and pCMV-dR8.91 vectors in 293T cells to
generate lentivirus, as previously described 26. One day prior to transfection, 850,000 293T
cells were seeded per well/plasmid. Roche X-tremeGENE 9 was used to transfect 293T cells
according to the manufacturer’s protocols (100 ng VSVG, 900 ng pCMV-dR8.91, and 1 ug
plasmid with 6 uL transfection reagent for each well/plasmid). 18 hours after transfection,
high serum (30% Gibco 16000 FBS in DMEM) media was added. Virus was harvested at 24
and 48 hours, pooled, and frozen at −80C in single-use aliquots26.
Lentiviral infection was performed as previously described 26. Cells were seeded at a density
of 1500–2500 cells per well, depending on cell type, in a 96-well plate in RPMI 1640
medium (200 μL total) supplemented with 5% fetal bovine serum and 2mM glutamine.
Fifteen hours after plating, cell culture medium was exchanged with fresh medium
containing Polybrene (8 μg/mL) and viral supernatant. Plates were centrifuged for 30
minutes at 2000 rpm and 37°C, after which the medium was replaced. Twenty-four hours
later, cells were selected for infection by adding puromycin to cell culture medium (2 μg/
ml). Uninfected control cells demonstrated 100% cell death within 48 hours. Seven days
following plating, cells were washed with PBS and fixed using 4% paraformaldehyde for 20
minutes at room temperature. Cells were stained using Hoechst 33342 dye (Invitrogen)
according to manufacturer’s specifications, imaged using ImageXpress Micro (Molecular
Devices), and counted using the “count nuclei” module of MetaXpress (Molecular Devices).
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experiments were performed using at least four independent cell cultures.
For MTHFD2 mRNA and protein measurements following shRNA knockdown, HCT116
cells were infected with lentiviral shRNA vectors in 6-well dishes as described 26. Seven
days following infection, mRNA was isolated from cells using an RNeasy kit (Qiagen), and
qRT-PCR was performed for MTHFD2 and HPRT using the Taqman assays (Applied
Biosystems, assay ID Hs01074341_g1 and Hs99999909_m1, respectively), according to
manufacturer’s instructions. qRT-PCR data is expressed as ΔΔCT values. For western blot
analysis, whole cell lysates were prepared and resolved by SDS-PAGE, followed by transfer
to a PVDF membrane using the Trans-Blot Turbo Transfer System. Membranes were
stained using primary antibody for ATP5A (Abcam Mouse Monoclonal, no. AB147480,
1:100,000) or MTHFD2 (Abcam Mouse Monoclonal, no. AB56772, 1:500), followed by
secondary antibody (Polyclonal Sheep anti-IgG mouse antibody, no. NA931V, 1:10,000).
Signal was detected using enhanced chemiluminescence. Full images of western blots are
provided in Supplementary Fig. 3a. For assay of MTHFD2 activity, 1×106 cells were lysed
using 1% Triton-X and MTHFD2 activity was measured in lysate as previously described28.
Transient siRNA knockdown
siRNA oligonucleotides targeting MTHFD2 were from Dharmacon, catalog# J-009349-10,
J-009349-11, J-009349-12, D-009349-02, D-0093848-03 and D-009349-04; referred to in
this study as siD2-10, siD2-11, siD2-12, siD2-2, siD2-3 and siD2-3, respectively. Control
siRNAs were Dharmacon ON-TARGET, referred to as siCtrl1, and Dharmacon siGenome,
referred to as siCtrl-2. Cells were transfected 24 hrs after seeding (at 40–60% confluence)
with 10 nM oligonucleotide, using the INTERFERin transfection reagent (Polyplus
Transfection). Western blot analysis was performed on cells seeded at 150,000 cells/well in
a 6-well plate and lysed in 2x Laemmli sample loading buffer 48 hours h after siRNA
transfection. Lysates were separated by 10% Mini-PROTEAN® TGX™ Precast Gel (Bio-
Rad), transferred to 0.45 μm nitrocellulose membrane (Bio-Rad) and blocked in 5% milk in
TBST. The following antibodies were used for immunoblotting: monoclonal mouse β-actin
antibody (Sigma-Aldrich, 1:30,000), monoclonal mouse MTHFD2 (Abnova, no.
H00010797-M01, 1:500) and anti-Mouse IgG (H+L) HRP conjugated (Pierce, 1:100,000).
Full images of western blots are provided in Supplementary Fig. 3b.
For assessment of cellular proliferation following transient siRNA transfection, cells were
seeded at 4,000 cells/well in a 96-well plate 24h prior to siRNA transfections and lysed at
indicated time points using CyQuant Cell Proliferation Assay (Invitrogen) according to
manufacturer’s instructions. Binding of CyQuant to DNA was analyzed by measuring
fluorescence in a VICTOR2 plate reader (PerkinElmer).
Flow cytometric measurement of cell death
Cells were seeded at 106 cells/100mm dish 24h prior to siRNA transfections. Cells were
collected by trypsinization at indicated time-points, pelleted for 5 min at 1500 rpm, rinsed
twice in ice-cold PBS and then resuspended in 0.01 M HEPES/NaOH (pH 7.4), 0.14 M
NaCl, 2.5 mM CaCl2. Cell suspension was diluted to a concentration of 5 × 105 cells/mL;
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t2.5 × 105 cells were transferred to a 5 mL culture tube and Propidium Iodide (PI, BD
PharMingen) was added to a concentration of 0.5 ug/mL; cells were gently vortexed and
incubated for 15 min at 25°C in the dark. Samples were analyzed within 1 hrs in a CyAn
ADP Analyzer (Beckamn Coulter), with flow rate approximately 300 events / s and a total
of 25,000 events were gated. Debris and doublets were excluded using forward scatter and
pulse width before gating of PI-positive populations.
Immunohistochemistry
Specimens containing normal and/or cancer tissues were collected in accordance with
approval from the local ethics committee (ref # Ups 02-577) and according to Swedish rules
and legislation. Tissue microarrays holding samples from the different cancer types as well
as from normal tissues were produced as previously described 38. Briefly, tissue samples
were fixed with formalin and embedded in paraffin; 2–3 tissue cylinders from representative
areas were punched out and assembled in a recipient tissue microarray block with pre-
punched holes. 4 μm sections were then cut and placed on Superfrost Plus microscope slides
(Thermo Fisher Scientific, Fremont, CA, USA) for immunohistochemical staining. Slides
were deparaffinized in xylene, hydrated in graded alcohols and blocked for endogenous
peroxidase for 5 min in 0.3% H2O2 diluted in 95% ethanol. Heat-induced epitope retrieval
was done in a decloaking chamber (Biocare Medical) with citrate buffer at pH 6.0 for 4 min
at 125° C. Before staining, slides were immersed in wash buffer containing 0.2% Tween-20
for 15 min to avoid surface tension. Staining was performed in an Autostainer 480S
instrument (Thermo Fisher Scientific) at room temperature with the following steps: Ultra V
block (Thermo Fisher Scientific, no. TA-125-UB) 5 min, primary antibody 30 min, primary
antibody enhancer (Thermo Fisher Scientific, no. TL-125-PB) 20 min, UltraVision LP HRP
polymer (Thermo Fisher Scientific, no. TL-125-PH) 30 min, and diaminobenzidine (Thermo
Fisher Scientific, no. TA-125-HDX) 5 min × 2 times. MTHFD2 primary antibody was from
Abnova (mouse monoclonal, no. H00010797-M01). Between incubations, slides were rinsed
in wash buffer. Slides were counter-stained with Mayer’s hematoxylin (Histolab,
Gothenburg, Sweden, ref. 01820), dehydrated and mounted on cover slips using pertex
(Histolab, ref. 00871.0500). Two independent observers evaluated staining for all samples,
blinded to the identity of the antibodies used. Staining intensity was classified (negative,
weak, moderate, strong) and fraction of positive cells (0, <25%, 25–75%, >75%) were
estimated separately for tumor cells and tumor stroma.
Survival analysis
Six independent large cohorts of cancer patients for which survival data for at least a decade
was available were examined. Microarray data from Chin et al. 39 and van de Vijver et al. 40,
were downloaded from the Lawrence Berkeley National Laboratory (http://cancer.lbl.gov/
breastcancer/list_data.php?id=9) and Rosetta Inpharmatics (http://www.rii.com/publications/
2002/nejm.html), respectively. Microarray data from the Desmedt et al. 41, Pawitan et al. 42,
Miller et al. 43 and Kao et al. 44 studies are available from the NCBI Gene Expression
Omnibus, accessions GSE7390, GSE1456, GSE3494, and GSE20685, respectively. Survival
data and clinical parameters were obtained from the original reports. Patients were split into
“positive” or “negative” based on above- or below-median expression of the MTHFD2
mRNA, and Kaplan-Meier curves were derived for these groups. Hazard ratios were
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testimated using Cox’s proportional hazard model 45. Groups were tested for significant
differences using the logrank test and meta-analysis was performed using the method of
DerSimonian and Laird 46.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Transcriptional regulation of metabolic pathways in human tumors
(a) Differential expression (Z-score) distributions for 51 tumor-vs-normal data sets
representing 19 tumor types are shown as violin plots (gray). Dots indicate Z-score for
MTHFD2 in each study; red color denotes significance at < 5% false discovery rate (FDR).
(b) Distribution of meta-analysis scores for all 20,103 genes interrogated across the 51 data
sets. Gene symbols indicated, see text for further description. (c) Metabolic pathways
detected as strongly over-expressed (among top 50 metabolic enzymes; red gene symbols)
or under-expressed (among bottom 50 metabolic enzymes; blue gene symbols) in tumors.
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t(d) Schematic of one-carbon metabolism with over-expressed (red) and under-expressed
(blue) genes indicated. Gray symbols, not measured. (e) Gene set enrichment analysis for
the set of 35 embryonic metabolic enzymes compared against mRNAs for all enzymes.
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tFigure 2. MTHFD2 expression in transformed compared to normal proliferating cells
(a) mRNA expression levels in normal postmitotic (open bars), normal proliferating (black
bars) and transformed cells or tissues (red bars) for MTHFD2 and four established cancer
drug targets. Normal hematopoietic cell fractions with strong expression are indicated. (b)
Quantile-quantile plot for the ratio of minimal expression among transformed cells to
maximum expression among normal (proliferating and postmitotic) cells, defined as in (a),
for each of the 12,529 human mRNAs measured. Randomized quantiles (X-axis) were
obtained by permuting samples. MTHFD2 mRNA is indicated. (c) mRNA expression of
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thuman MTHFD2 or mouse Mthfd2 and four established cancer drug targets during mouse
liver regeneration following partial hepatectomy (left); human fibroblasts proliferating in
response to serum stimulation (center); and human CD4+ T lymphocytes activated by CD3
and CD28 antibodies (right). Red line indicates Mthfd2/MTHFD2. (d) mRNA expression of
human MTHFD2 (left) and mouse Mthfd2 (right) during early embryonic development.
Error bars denote standard deviation (n = 3). (e) mRNA expression of mouse Mthfd2 during
embryonic development of liver (left) and hypothalamus (right). Error bars denote standard
deviation (n = 2).
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tFigure 3. MTHFD2 protein expression in human tumors
(a) Top, fraction of samples with none, weak, moderate or strong immunohistochemistry
staining for MTHFD2 in transformed cells, across 16 solid tumor types. Bottom, same
analysis as above for stromal cells. For each tumor type, tumors from 9–12 individuals were
examined. (b) Representative images from each of the 16 tumor types summarized in (a),
exemplifying negative (N), weak (W), moderate (M) or strong (S) staining intensities. Up
arrow, stromal cells; down arrow, cancer cells. Scale bars represent 100um.
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Table 2
Top 50 metabolic enzymes frequently under-expressed in human tumors
Negative scores denotes number of data sets (of 51 total) where each gene was significantly under-expressed
at a false discovery rate (FDR) of 5%, as in Fig. 1.
Score Symbol Description
−24 ASPA aspartoacylase
−23 AOX1 aldehyde oxidase 1
−22 GPX3 glutathione peroxidase 3 (plasma)
−21 ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide
−20 PTGDS prostaglandin D2 synthase 21kDa (brain)
−20 MAOB monoamine oxidase B
−20 AMT aminomethyltransferase
−19 COX7A1 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle)
−17 UST uronyl-2-sulfotransferase
−17 SOD3 superoxide dismutase 3, extracellular
−17 PTGIS prostaglandin I2 (prostacyclin) synthase
−17 ADH1C alcohol dehydrogenase 1C (class I), gamma polypeptide
−16 PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, beta
−16 PDE2A phosphodiesterase 2A, cGMP-stimulated
−16 CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5
−16 ALDH2 aldehyde dehydrogenase 2 family (mitochondrial)
−16 ALDH1A1 aldehyde dehydrogenase 1 family, member A1
−15 ECHDC2 enoyl CoA hydratase domain containing 2
−15 DUOX1 dual oxidase 1
−15 ST6GALNAC2 ST6-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2
−15 PPAP2B phosphatidic acid phosphatase type 2B
−15 PLCL1 phospholipase C-like 1
−15 IDI1 isopentenyl-diphosphate delta isomerase 1
−15 ALDH9A1 aldehyde dehydrogenase 9 family, member A1
−15 ACACB acetyl-CoA carboxylase beta
−14 MAN1C1 mannosidase, alpha, class 1C, member 1
−14 CHST3 carbohydrate (chondroitin 6) sulfotransferase 3
−14 MAOA monoamine oxidase A
−14 CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1
−14 ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide
−14 ALDH3A2 aldehyde dehydrogenase 3 family, member A2
−14 ADH1A alcohol dehydrogenase 1A (class I), alpha polypeptide
−13 NMRK1 nicotinamide riboside kinase 1
−13 INPP5A inositol polyphosphate-5-phosphatase, 40kDa
−13 HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1
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Score Symbol Description
−13 CYP27A1 cytochrome P450, family 27, subfamily A, polypeptide 1
−13 CHKB choline kinase beta
−13 CAT catalase
−12 ACOX2 acyl-CoA oxidase 2, branched chain
−12 SRD5A2 steroid-5-alpha-reductase, alpha polypeptide 2
−12 SLC6A4 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4
−12 PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha)
−12 HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)
−12 GSTM1 glutathione S-transferase mu 1
−12 GATM glycine amidinotransferase (L-arginine:glycine amidinotransferase)
−12 ETFDH electron-transferring-flavoprotein dehydrogenase
−12 CDO1 cysteine dioxygenase, type I
−12 ATP6V1E1 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1
−12 ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide
−12 SLC25A4 solute carrier family 25 (mitochondrial carrier; ANT), member 4
Nat Commun. Author manuscript; available in PMC 2014 July 22.